CC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Chemours Co is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock is experiencing significant downward price pressure, and while there are some positive catalysts, the financial performance and market sentiment suggest caution. Holding the stock or waiting for better entry points is recommended.
The technical indicators show mixed signals. The MACD is positive but contracting, RSI is neutral at 64.156, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock has broken below key support levels, with a post-market price of $18.3, well below the pivot of $19.376 and nearing S1 at $17.34.
Analysts have raised price targets recently, with Truist, BMO Capital, and RBC Capital maintaining Buy or Outperform ratings.
Sale of the Taiwan TiO2 site for $360M provides liquidity for debt reduction and future growth.
Chemours declared a dividend, reflecting commitment to shareholder returns.
Significant post-market price drop (-10.34%) following a regular market decline (-3.50%), indicating bearish sentiment.
Financial performance in Q4 2025 showed a net loss of $386M and declining revenue (-4.59% YoY).
Litigation charges and slow demand in Europe/Asia remain headwinds.
Chemours reported flat revenue of $5.8 billion for 2025 and a net loss of $386 million due to litigation charges. Q4 2025 revenue dropped by 4.59% YoY, and gross margin declined by 40.55% YoY. However, EPS improved significantly to -2.57, up 5040% YoY, due to adjustments.
Analysts have raised price targets recently, with Truist increasing to $21, BMO Capital to $20, and RBC Capital to $18. Most analysts maintain Buy or Outperform ratings, citing liquidity improvements and long-term growth potential in low-GWP refrigerants. However, JPMorgan remains Neutral with a lower target of $13.
